Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $18.6750 (-11.07%) ($18.4500 - $20.7550) on Mon. Aug. 10, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.26% (three month average) | RSI | 31 | Latest Price | $18.6750(-11.07%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -2% a day on average for past five trading days. | Weekly Trend | TGTX declines -3% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Value stock rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(63%) ARKG(59%) ARKK(56%) IWO(56%) IBB(55%) | Factors Impacting TGTX price | TGTX will decline at least -2.13% in a week (0% probabilities). VIXM(-35%) VXX(-33%) UUP(-18%) DRIV(-4%) XLC(-3%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.13% (StdDev 4.26%) | Hourly BBV | 0 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | Resistance Level | $21.12 | 5 Day Moving Average | $20.33(-8.14%) | 10 Day Moving Average | $20.21(-7.6%) | 20 Day Moving Average | $21.12(-11.58%) | To recent high | -22.7% | To recent low | 11.2% | Market Cap | $2.365b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |